Aim: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been reported to increase hemoglobin levels; however, little is known about the magnitude of their anemia-improving effect in patients with advanced chronic kidney disease. Here, SLC5A2 is linked to chronic kidney disease.